Skip to main content
OpenTrials

Clinical trial condition

Choroid Diseases

Explore clinical trials studying Choroid Diseases. Study availability and eligibility vary by location and protocol.

229 public trials 17 recruiting studies
Refine in advanced search Browse all conditions

Choroid Diseases trial results

Completed

Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

NCT03584165

Conditions
Choroid Diseases, Choroideremia, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +6 more
Locations
  • UCLA - Jules Stein Eye Institute Los Angeles, California, United States
  • Vitreo Retinal Associates PA - The Millennium Center Gainesville, Florida, United States
  • University of Miami Miami, Florida, United States
  • Johns Hopkins Hospital Baltimore, Maryland, United States
View all 25 locations
View Trial Details
Completed

A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)

NCT05282953

Conditions
Choroid Diseases, Choroideremia, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +10 more
Locations
  • Save Sight Institute Sydney, New South Wales, Australia
  • Royal Adelaide Hospital Adelaide, South Australia, Australia
  • Harley Eye Clinic North Adelaide, South Australia, Australia
View Trial Details
Completed

Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy

NCT05666804

Conditions
Cardiovascular Diseases, Choroid Diseases, Choroidal Neovascularization, +16 more
Locations
  • Novartis Investigative Site Daegu, Dalseo Gu, South Korea
  • Novartis Investigative Site Bundang Gu, Gyeonggi-do, South Korea
  • Novartis Investigative Site Daejeon, Korea, South Korea
  • Novartis Investigative Site Seoul, Korea, South Korea
View all 15 locations
View Trial Details
Completed

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration

NCT04679935

Conditions
Age-Related Macular Degeneration, Choroid Diseases, Choroidal Neovascularization, +17 more
Locations
  • Novartis Investigative Site Regensburg, Bavaria, Germany
  • Novartis Investigative Site Frankfurt am Main, Hesse, Germany
  • Novartis Investigative Site Berlin, Germany
  • Novartis Investigative Site Bonn, Germany
View all 19 locations
View Trial Details

Related conditions